Community Letter from Roche: CHMP positive opinion for risdiplam tablet label update
We are pleased to share a community letter from Roche, announcing that the EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update to the European label for the risdiplam tablet.
This update will allow the risdiplam tablet to be administered via nasogastric and gastrostomy feeding tubes after dispersion in water.